Table 3.

Responses to camonsertib monotherapy in the TRESR trial

Tumor type	Enrollment gene	Allelic status	Other features	Prior PARP inhibitor	Prior platinum	Lines of prior therapy	Time on therapy (weeks)	Response	Best % change in TL from baseline
Ovarian	gBRCA1	Biallelic	BRCA1 reversion	Y	Y	6	48	RECIST cPR	−49.3
	gBRCA1	Biallelic		Y	Y	5	25	RECIST uPRa	−38.3
	gRAD51C	Biallelic		Y	Y	3	40+	RECIST cPRb	−100
	gRAD51C	Biallelic		Yc	Y	5	42+	CA-125	−12.5
	sSETD2	Unknown		N	Y	4	22+	RECIST cPR	−70
CRPC	sATM	Unknown		N	N	2	30	RECIST cPR	−33.7
	sATM	Biallelic		N	N	7	61+	PSA	−29.8
	gATM	Unknown		N	N	3	35+	PSAd	NA
	sCDK12	Biallelic		N	Y	6	25	RECIST cPR	−31.9
Breast	sBRCA1	Biallelic		N	N	7	18	RECIST uPR	−30.4
Melanoma	sBRCA2	Monoallelic	TMB-H; Sig 7 (UV light)	Y	N	5	41+	RECIST cPR	−69.9
HNSCC	sBRCA1	Monoallelic	TMB-H; Sig 2 + 13 (APOBEC)	N	Y	1	26	RECIST cPR	−36.7
Pancreatic	gATM	Unknown		N	Y	2	54+	RECIST cPR	−32.1
NSCLC	gATM	Biallelic		N	Y	3	37+e	RECIST cPRe	−31.4

^aPR unconfirmed due to progression of brain lesions though sustained reduction in TLs and 5/7 NTLs disappeared. ^bPatient had complete response of TLs (NTL still present). ^cTwo prior PARP inhibitors. ^dNon-measurable disease; >90% PSA decrease. ^euPR occurred at 37 weeks of treatment on 7 July 2022, after the 22 March 2022 data cut. ‘+’ indicates treatment ongoing at time of the 22 March 2022 data cut.

g, germline; N, no; NA, not available; s, somatic; Sig, signature; Y, yes.